LEXINGTON, Mass.--(BUSINESS WIRE)--SynapDx Corporation today announced that it has formed a collaboration with the Broad Institute of Harvard and MIT. The collaboration brings together scientists with leading expertise in computational biology and software engineering to accelerate advances in next generation sequencing.
SynapDx is currently conducting one of the largest prospective, multi-center studies to analyze blood from children undergoing clinical evaluation for autism spectrum disorder (ASD). The objective of the collaboration is to develop advanced next generation sequencing (NGS) analysis techniques to further enhance test accuracy and clinical utility in autism diagnostics.
"We are thrilled to be working with SynapDx. Our collaboration will enable us to really push the methods for variant detection in new directions," said Eric Banks, Group Leader of Genome Sequencing and Analysis at the Broad Institute.
“Our partnership with the Broad Institute helps advance our mission by developing powerful tools for the analysis of next generation sequencing data that will have broad application in the detection of autism and beyond,” said Mark DePristo, SynapDx Vice President of Informatics.
About SynapDx Corp.
SynapDx is a private company developing next generation laboratory testing services for the early detection of autism spectrum disorders (ASDs). SynapDx’s investors include, General Catalyst Partners, North Bridge Venture Partners, Google Ventures, LabCorp, The Kraft Group, Foundation Medical Partners, Casdin Capital and Windham Venture Partners. SynapDx was founded in 2010 and is based in Lexington, Mass.
